Clinical trial

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

NCT07158164

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-08-27

PhasePHASE4

Study timeline

Study start (actual)2025-08-27Date precision: day

Registry last updated2025-11-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Colorectal Neoplasmsunresolved

Breast Neoplasmsunresolved

Head and Neck Neoplasmsunresolved

Gastro-Intestinal Intraepithelial Neoplasiaunresolved

Interventions

Fluorouracil injectionDRUG · verified · RxNorm: fluorouracil Injection

XelodaDRUG · verified · RxNorm: Xeloda

Sponsors & collaborators

Rutgers, The State University of New Jerseylead sponsor

Mapped research locations

NewarkNew Jersey, United States3 New BrunswickNew Jersey, United States2 Toms RiverNew Jersey, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07158164 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.